Eledon Pharmaceuticals Inc Cash Flow Conversion Efficiency
Eledon Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) has a cash flow conversion efficiency ratio of -0.103x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.09 Million) by net assets ($136.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eledon Pharmaceuticals Inc (2012–2025)
Cash flow conversion efficiency of Eledon Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Eledon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Eledon Pharmaceuticals Inc share price for real-time trading data and today's change.
Eledon Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Eledon Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eledon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eledon Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see ELDN market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Etteplan Oyj
HE:ETTE
|
0.031x |
|
D2L Inc
TO:DTOL
|
0.402x |
|
Harvatek Corp
TW:6168
|
-0.006x |
|
Kejuruteraan Asastera Bhd
KLSE:0193
|
-0.273x |
|
TRG Latin America Acquisitions Corp. Class A Ordinary Shares
NASDAQ:TRGS
|
0.000x |
|
GRM Overseas Limited
NSE:GRMOVER
|
0.004x |
|
Sanstar Ltd
NSE:SANSTAR
|
0.064x |
|
Peninsula Group Ltd
TA:PEN
|
-0.033x |
Annual Cash Flow Conversion Efficiency for Eledon Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Eledon Pharmaceuticals Inc from 2012 to 2025. Review how financially flexible is Eledon Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $136.78 Million | $-62.34 Million | -0.456x | -13.91% |
| 2024-12-31 | $118.14 Million | $-47.27 Million | -0.400x | +15.56% |
| 2023-12-31 | $83.42 Million | $-39.53 Million | -0.474x | -40.34% |
| 2022-12-31 | $84.18 Million | $-28.42 Million | -0.338x | -91.51% |
| 2021-12-31 | $164.00 Million | $-28.91 Million | -0.176x | -120.90% |
| 2020-12-31 | $190.60 Million | $-15.21 Million | -0.080x | +94.55% |
| 2019-12-31 | $9.46 Million | $-13.86 Million | -1.464x | -78.40% |
| 2018-12-31 | $14.49 Million | $-11.89 Million | -0.821x | -6.84% |
| 2017-12-31 | $19.45 Million | $-14.94 Million | -0.768x | +43.51% |
| 2016-12-31 | $26.86 Million | $-36.52 Million | -1.360x | -103.53% |
| 2015-12-31 | $61.72 Million | $-41.24 Million | -0.668x | -227.38% |
| 2014-12-31 | $103.50 Million | $-21.12 Million | -0.204x | -172.87% |
| 2013-12-31 | $-55.27 Million | $-15.48 Million | 0.280x | +19.72% |
| 2012-12-31 | $-39.90 Million | $-9.33 Million | 0.234x | -- |
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more